|
All Business Categories
|
Antisoma plc
London, United Kingdom Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promisin... Acambis plc CB1, United Kingdom Acambis is a leading biotechnology company targeting infectious diseases with novel vaccines. Acambis' development-stage pipeline includes vaccines that could either offer improvem... Protherics PLC CHESHIRE, United Kingdom Protherics is a leading biopharmaceutical company focused on developing, manufacturing and marketing critical care and cancer products. We have developed two FDA approved products ... Oxagen Limited Oxfordshire, United Kingdom Oxagen is focused on becoming a significant biopharmaceutical company, developing a pipeline of novel drugs to treat inflammatory diseases. The Company has created a portfolio of v... CeNeS Pharmaceuticals plc CB24, United Kingdom CeNeS Pharmaceuticals plc (AIM: CEN), the biopharmaceutical company developing a new generation of pain management products, announces interim results for the six months ended 30 J... Oxfordshire, United Kingdom VASTox is a chemical genomics technology company that provides services to the pharmaceutical industry and discovers and develops proprietary novel drugs. The company's technology ... Vernalis plc BERKSHIRE, United Kingdom Vernalis is a speciality bio-pharmaceutical company focused on products marketed to specialist neurologists. The company has two marketed products, Frova® and Apokyn®, and a develo... Renovo Ltd M13, United Kingdom Renovo is a biopharmaceutical product company and is the world leader in scar prevention and reduction research, and the development of drugs to prevent and reduce scarring. The Co... TopoTarget Oxfordshire, United Kingdom The Company is committed to continuing its development as a niche oncology product company. The relatively shorter development time for its niche product candidates, e.g. SaveneTM ... Trigen Ltd London, United Kingdom Trigen previously announced the successful completion of a Phase I dose escalation study on TGN 167 using a classical rapid release tablet formulation. Trigen is developing TGN 167...
1
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[51]
[82]
[113]
Next
Last
|
